Twitter

Posts Tagged ‘sponsors’


Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis

Conditions :   Psoriasis;   Psoriatic Arthritis Interventions :   Drug: Apremilast 30 mg;   Drug: Etanercept 50 mg;   Drug: Placebo tablet;   Drug: Placebo injection (saline) Sponsors :   Celgene Corporation;   Celgene Corporation Recruiting – verified September 2012

Read More...

MRI for the Early Evaluation of Acute Intracerebral Hemorrhage

Conditions :   Cerebral Hemorrhage;   Intracranial Arteriovenous Malformations;   Intracranial Hemorrhage, Hypertensive;   Brain Neoplasms Intervention :   Device: MRI Scan with the specified sequences below: Sponsors :   Bispebjerg Hospital;   Bispebjerg Hospital Recruiting – verified September 2012

Read More...

Cy/ Dex/ Rapa/ HCQ for Rel/Ref MM

Condition :   Multiple Myeloma Interventions :   Drug: Hydroxychloroquine;   Drug: Rapamycin Sponsors :   OHSU Knight Cancer Institute;   OHSU Knight Cancer Institute Not yet recruiting – verified September 2012

Read More...

A Study of Vemurafenib Alone And Vemurafenib in Combination With GDC-0973 in Patients With Malignant Melanoma

Condition :   Malignant Melanoma Interventions :   Drug: vemurafenib;   Drug: Placebo;   Drug: GDC-0973 Sponsors :   Hoffmann-La Roche;   Hoffmann-La Roche Not yet recruiting – verified September 2012

Read More...

Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON)

Condition :   Primary Breast Cancer Interventions :   Drug: Docetaxel;   Drug: Trastuzumab;   Drug: Bevacizumab;   Drug: Epirubicin;   Drug: Cyclophosphamid Sponsors :   West German Study Group;   West German Study Group;   Roche Pharma AG;   Sanofi-Aventis Not yet recruiting – verified September 2012

Read More...

Triciribine and Carboplatin in Ovarian Cancer

Condition :   Ovarian Cancer Interventions :   Drug: Triciribine;   Drug: Carboplatin Sponsors :   H. Lee Moffitt Cancer Center and Research Institute;   H. Lee Moffitt Cancer Center and Research Institute;   Department of Defense;   Cahaba Pharmaceuticals Not yet recruiting – verified September 2012

Read More...

Comparison of Surgical Approach to Endoscopic Pituitary Adenoma Resection

Conditions :   Pituitary Adenoma;   Posterior Septectomy;   Stamm Approach;   Quality of Life Interventions :   Procedure: Stamm Approach;   Procedure: Posterior Septectomy Sponsors :   University of Calgary;   University of Calgary Recruiting – verified September 2012

Read More...

Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot be Removed by Surgery

Conditions :   Childhood Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma Interventions :   Drug: tivantinib;   Drug: erlotinib hydrochloride Sponsors :   National Cancer Institute (NCI);   National Cancer Institute (NCI) Recruiting – verified September 2012

Read More...

A Phase II Study of Cabozantinib (XL184) in Patients With Advanced/Metastatic Urothelial Carcinoma

Conditions :   Micropapillary Cancer of the Bladder;   Squamous Cell Carcinoma of the Bladder;   Bladder Cancer With Bone Metastases;   Bladder Cancer;   Small Cell Cancer of the Bladder;   Urachal Cancer;   Sarcomatoid Bladder Cancer Interventions :   Drug: Cabozantinib;   Procedure: FDG PET CT;   Procedure: NaF PET CT Sponsors :   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI) Recruiting – verified September 2012

Read More...

Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma

Condition :   Esophageal Squamous Cell Carcinoma Resectable Intervention :   Drug: Nimotuzumab combined with paclitaxel and cisplatin Sponsors :   Zhejiang Cancer Hospital;   Zhejiang Cancer Hospital Recruiting – verified September 2012

Read More...